Delivery of drugs applied topically to the skin

Expert Review of Dermatology

Volumn 7, Issue 4, 2012, Pages 383-397

  Leite Silva, Vânia Rodrigues ^a,b   De Almeida, Mariana Mandelli ^c,d   Fradin, Aurélie ^e   Grice, Jeffrey Ernest ^b   Roberts, Michael Stephen ^b,f  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d MINISTRY OF EDUCATION OF BRAZIL   (Brazil)

^e UNIVERSITÉ DE RENNES 1   (France)

^f UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

formulation; nanosystems; penetration enhancement; skin barrier; stratum corneum; topical application

Indexed keywords

ALPHA INTERFERON; AMINOLEVULINIC ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIBIOTIC AGENT; APOMORPHINE; BENZOCAINE; BENZOPHENONE; CELECOXIB; CHLORHEXIDINE; ESTRADIOL; FINASTERIDE; FLUOROURACIL; GLUCOCORTICOID; INDOMETACIN; INTERLEUKIN 2; KETOPROFEN; LIDOCAINE; MELATONIN; MINOXIDIL; NANOMATERIAL; OXYBENZONE; PLASMID DNA; RETINOIC ACID; SALBUTAMOL; SMALL INTERFERING RNA; SULISOBENZONE; UBIDECARENONE; UNINDEXED DRUG; VACCINE; ZIDOVUDINE;

AGING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; ELECTRICITY; ELECTROPORATION; ETHNICITY; HUMAN; HYDRATION; IN VITRO STUDY; IN VIVO STUDY; IONTOPHORESIS; MASSAGE; MICROEMULSION; MICRONEEDLE; NANOEMULSION; NEEDLE; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SKIN; SKIN ABSORPTION; SKIN DEFECT; SKIN PERMEABILITY; STRATUM CORNEUM; TOPICAL DRUG ADMINISTRATION; ULTRASOUND; VISCOSITY;

EID: 84866661647     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/edm.12.32     Document Type: Review

References (166)

1. Hadgraft J, Lane ME. Transepidermal water loss and skin site: a hypothesis. Int. J. Pharm. 373(1-2), 1-3 (2009).
2. Grice JE, Prow TW, Kendall MA, Roberts MS. Electrical and physical methods of skin penetration enhancement. In: Topical and Transdermal Drug Delivery and Development. Watkinson AC, Benson HA (Eds). John Wiley & Sons Inc., NJ, USA, 43-65 (2012).
3. Roberts MS, Cross SE, Pellett MA. Skin transport. In: Dermatological and Transdermal Formulations. Walters KA (Ed.). Marcel Dekker Inc., NY, USA, 89-196 (2002).
4. Magnusson BM, Anissimov YG, Cross SE, Roberts MS. Molecular size as the main determinant of solute maximum flux across the skin. J. Invest. Dermatol. 122(4), 993-999 (2004).
5. Anissimov YG, Roberts MS. Diffusion modeling of percutaneous absorption kinetics. 1. Effects of flow rate, receptor sampling rate, and viable epidermal resistance for a constant donor concentration. J. Pharm. Sci. 88(11), 1201-1209 (1999).
6. Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J. Pharm. Sci. 50, 874-875 (1961).
7. Mitragotri S, Anissimov YG, Bunge AL et al. Mathematical models of skin permeability: an overview. Int. J. Pharm. 418(1), 115-129 (2011).
8. Potts RO, Guy RH. Predicting skin permeability. Pharm. Res. 9(5), 663-669 (1992).
9. Potts RO, Guy RH. A predictive algorithm for skin permeability: the effects of molecular size and hydrogen bond activity. Pharm. Res. 12(11), 1628-1633 (1995).
10. Winsor T, Burch GE. Differential roles of layers of human epigastric skin on diffusion rate of water. Arch. Intern. Med. (Chic.) 74(6), 428-436 (1944).
11. Blank IH. Further observations on factors which influence the water content of the stratum corneum. J. Invest. Dermatol. 21(4), 259-271 (1953).
12. Fluhr JW, Feingold KR, Elias PM. Transepidermal water loss reflects permeability barrier status: validation in human and rodent in vivo and ex vivo models. Exp. Dermatol. 15(7), 483-492 (2006).
13. Tagami H, Yoshikuni K. Interrelationship between water-barrier and reservoir functions of pathologic stratum corneum. Arch. Dermatol. 121(5), 642-645 (1985).
14. Werner Y, Lindberg M. Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis. Acta Derm. Venereol. 65(2), 102-105 (1985).
15. Grubauer G, Feingold KR, Harris RM, Elias PM. Lipid content and lipid type as determinants of the epidermal permeability barrier. J. Lipid Res. 30(1), 89-96 (1989).
16. Elias PM, Friend DS. The permeability barrier in mammalian epidermis. J. Cell Biol. 65(1), 180-191 (1975).
17. Swartzendruber DC, Wertz PW, Kitko DJ, Madison KC, Downing DT. Molecular models of the intercellular lipid lamellae in mammalian stratum corneum. J. Invest. Dermatol. 92(2), 251-257 (1989).
18. Proksch E, Brandner JM, Jensen JM. The skin: an indispensable barrier. Exp. Dermatol. 17(12), 1063-1072 (2008).
19. Benson HA. Transdermal drug delivery: penetration enhancement techniques. Curr. Drug Deliv. 2(1), 23-33 (2005).
20. Leite E Silva VR, Schulman MA, Ferelli C et al. Hydrating effects of moisturizer active compounds incorporated into hydrogels: in vivo assessment and comparison between devices. J. Cosm. Dermatol. 8(1), 32-39 (2009).
21. Benson HAE. Skin structure, function, and permeation. In: Topical and Transdermal Drug Delivery and Development. Watkinson AC, Benson HA (Eds). John Wiley & Sons Inc., NJ, USA, 3-22 (2012).
22. Kleesz P, Darlenski R, Fluhr JW. Full-body skin mapping for six biophysical parameters: baseline values at 16 anatomical sites in 125 human subjects. Skin Pharmacol. Physiol. 25(1), 25-33 (2012).
23. Batisse D, Bazin R, Baldeweck T, Querleux B, Lévêque JL. Influence of age on the wrinkling capacities of skin. Skin Res. Technol. 8(3), 148-154 (2002).
24. Lober CW, Fenske NA. Photoaging and the skin: differentiation and clinical response. Geriatrics 45(4), 36-40, 42 (1990).
25. Voegeli R, Rawlings AV, Doppler S, Heiland J, Schreier T. Profiling of serine protease activities in human stratum corneum and detection of a stratum corneum tryptase-like enzyme. Int. J. Cosmet. Sci. 29(3), 191-200 (2007).
26. Fenske NA, Lober CW. Structural and functional changes of normal aging skin. J. Am. Acad. Dermatol. 15(4 Pt 1), 571-585 (1986).
27. Roskos KV, Bircher AJ, Maibach HI, Guy RH. Pharmacodynamic measurements of methyl nicotinate percutaneous absorption: the effect of aging on microcirculation. Br. J. Dermatol. 122(2), 165-171 (1990).
28. Roskos KV, Guy RH. Assessment of skin barrier function using transepidermal water loss: effect of age. Pharm. Res. 6(11), 949-953 (1989).
29. Giusti F, Martella A, Bertoni L, Seidenari S. Skin barrier, hydration, and pH of the skin of infants under 2 years of age. Pediatr. Dermatol. 18(2), 93-96 (2001).
30. Berardesca E, Maibach HI. Racial differences in sodium lauryl sulphate induced cutaneous irritation: black and white. Contact Derm. 18(2), 65-70 (1988).
31. Kompaore F, Marty JP, Dupont C. In vivo evaluation of the stratum corneum barrier function in blacks, Caucasians and Asians with two noninvasive methods. Skin Pharmacol. 6(3), 200-207 (1993).
32. Warrier GA, Kligman AM, Harper RA et al. A comparison of black and white skin using noninvasive methods. J. Soc. Cosmet. Chem. 47, 229-240 (1996).
33. Muizzuddin N, Hellemans L, Van Overloop L, Corstjens H, Declercq L, Maes D. Structural and functional differences in barrier properties of African American, Caucasian and East Asian skin. J. Dermatol. Sci. 59(2), 123-128 (2010).
34. Cua AB, Wilhelm KP, Maibach HI. Frictional properties of human skin: relation to age, sex and anatomical region, stratum corneum hydration and transepidermal water loss. Br. J. Dermatol. 123(4), 473-479 (1990).
35. Muizzuddin N, Marenus KD, Schnittger SF, Sullivan M, Maes DH. Effect of systemic hormonal cyclicity on skin. J. Cosmet. Sci. 56(5), 311-321 (2005).
36. Chiang A, Tudela E, Maibach HI. Percutaneous absorption in diseased skin: an overview. J. Appl. Toxicol. 8, 537-563 (2012).
37. Aalto-Korte K, Turpeinen M. Quantifying systemic absorption of topical hydrocortisone in erythroderma. Br. J. Dermatol. 133(3), 403-408 (1995).
38. Colombo G, Zucchi A, Allegra F, Colombo P, Zani F, Santi P. In vitro and in vivo study of 5-methoxypsoralen skin concentration after topical application. Skin Pharmacol. Appl. Skin Physiol. 16(2), 130-136 (2003).
39. Smits T, Robles CA, van Erp PE, van de Kerkhof PC, Gerritsen MJ. Correlation between macroscopic fluorescence and protoporphyrin IX content in psoriasis and actinic keratosis following application of aminolevulinic acid. J. Invest. Dermatol. 125(4), 833-839 (2005).
40. Hata M, Tokura Y, Takigawa M et al. Assessment of epidermal barrier function by photoacoustic spectrometry in relation to its importance in the pathogenesis of atopic dermatitis. Lab. Invest. 82(11), 1451-1461 (2002).
41. Jakasa I, de Jongh CM, Verberk MM, Bos JD, Kezic S. Percutaneous penetration of sodium lauryl sulphate is increased in uninvolved skin of patients with atopic dermatitis compared with control subjects. Br. J. Dermatol. 155(1), 104-109 (2006).
42. Jakasa I, Verberk MM, Esposito M, Bos JD, Kezic S. Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. J. Invest. Dermatol. 127(1), 129-134 (2007).
43. Ortiz PG, Hansen SH, Shah VP, Menné T, Benfeldt E. The effect of irritant dermatitis on cutaneous bioavailability of a metronidazole formulation, investigated by microdialysis and dermatopharmacokinetic method. Contact Derm. 59(1), 23-30 (2008).
44. Moan J, Ma LW, Iani V. On the pharmacokinetics of topically applied 5-aminolevulinic acid and two of its esters. Int. J. Cancer 92(1), 139-143 (2001).
45. Roberts MS, Dancik Y, Prow TW et al. Non-invasive imaging of skin physiology and percutaneous penetration using fluorescence spectral and lifetime imaging with multiphoton and confocal microscopy. Eur. J. Pharm. Biopharm. 77(3), 469-488 (2011).
46. Otto A, du Plessis J, Wiechers JW. Formulation effects of topical emulsions on transdermal and dermal delivery. Int. J. Cosmet. Sci. 31(1), 1-19 (2009).
47. Grice JE, Ciotti S, Weiner N, Lockwood P, Cross SE, Roberts MS. Relative uptake of minoxidil into appendages and stratum corneum and permeation through human skin in vitro. J. Pharm. Sci. 99(2), 712-718 (2010).
48. Zhang Q, Li P, Roberts MS. Maximum transepidermal flux for similar size phenolic compounds is enhanced by solvent uptake into the skin. J. Control. Release 154(1), 50-57 (2011).
49. Kurul E, Hekimoglu S. Skin permeation of two different benzophenone derivatives from various vehicles. Int. J. Cosmet. Sci. 23(4), 211-218 (2001).
50. Longo DP. [Collection, characterization and release studies; in vitro and in vivo permeation of microstructured systems containing caffeine]. PhD thesis, São Paulo State University 'Julio de Mesquite Filho', São Paulo, Brazil (2006).
51. Wirén K, Frithiof H, Sjöqvist C, Lodén M. Enhancement of bioavailability by lowering of fat content in topical formulations. Br. J. Dermatol. 160(3), 552-556 (2009).
52. Goodman H. The acid mantle of the skin surface. Ind. Med. Surg. 27(2), 105-108 (1958).
53. Dikstein S, Zlotogorski A. Measurement of skin pH. Acta Derm. Venereol. Suppl. (Stockh.) 185, 18-20 (1994).
54. Schmid-Wendtner MH, Korting HC. The pH of the skin surface and its impact on the barrier function. Skin Pharmacol. Physiol. 19(6), 296-302 (2006).
55. Prow TW, Grice JE, Lin LL et al. Nanoparticles and microparticles for skin drug delivery. Adv. Drug Deliv. Rev. 63(6), 470-491 (2011).
56. Baroli B. Penetration of nanoparticles and nanomaterials in the skin: fiction or reality? J. Pharm. Sci. 99(1), 21-50 (2010).
57. Cross SE, Pugh WJ, Hadgraft J, Roberts MS. Probing the effect of vehicles on topical delivery: understanding the basic relationship between solvent and solute penetration using silicone membranes. Pharm. Res. 18(7), 999-1005 (2001).
58. Gallagher SJ, Trottet L, Carter TP, Heard CM. Effects of membrane type and liquid/liquid phase boundary on in vitro release of ketoprofen from gel formulations. J. Drug Target. 11(6), 373-379 (2003).
59. Gallagher SJ, Heard CM. Solvent content and macroviscosity effects on the in vitro transcutaneous delivery and skin distribution of ketoprofen from simple gel formulations. Skin Pharmacol. Physiol. 18(4), 186-194 (2005).
60. Kumar KS, Kumar PM, Kumar KA et al. A new three-component reaction: green synthesis of novel isoindolo[2,1-a] quinazoline derivatives as potent inhibitors of TNF-α. Chem. Commun. (Camb.) 47(17), 5010-5012 (2011).
61. Klang S, Abdulrazik M, Benita S. Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution. Pharm. Dev. Technol. 5(4), 521-532 (2000).
62. Kitagawa S, Kasamaki M. Enhancement effects of double-chained cationic surfactants of n-dimethyldialkylammoniums on permeability of salicylate through guinea pig dorsal skin. Chem. Pharm. Bull. 50(10), 1370-1372 (2002).
63. Javadzadeh Y, Shokri J, Hallaj-Nezhadi S, Hamishehkar H, Nokhodchi A. Enhancement of percutaneous absorption of finasteride by cosolvents, cosurfactant and surfactants. Pharm. Dev. Technol. 15(6), 619-625 (2010).
64. Kreilgaard M. Influence of microemulsions on cutaneous drug delivery. Adv. Drug Deliv. Rev. 54(Suppl. 1), S77-S98 (2002).
65. Chen H, Chang X, Weng T et al. A study of microemulsion systems for transdermal delivery of triptolide. J. Control. Release 98(3), 427-436 (2004).
66. Garti N, Anserin A. Microemulsions for solubilization and delivery of nutraceuticals and drugs. In: Microencapsulation: Methods and Industrial Applications. Benita S (Ed.). Taylor & Francis Group, NY, USA, 345-428 (2006).
67. Kogan A, Garti N. Microemulsions as transdermal drug delivery vehicles. Adv. Colloid Interface Sci. 123-126, 369-385 (2006).
68. Shakeel F, Baboota S, Ahuja A, Ali J, Shafiq S. Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion. J. Nanobiotechnology 6, 8 (2008).
69. Sadighi A, Ostad SN, Rezayat SM, Foroutan M, Faramarzi MA, Dorkoosh FA. Mathematical modelling of the transport of hydroxypropyl-β-cyclodextrin inclusion complexes of ranitidine hydrochloride and furosemide loaded chitosan nanoparticles across a Caco-2 cell monolayer. Int. J. Pharm. 422(1-2), 479-488 (2012).
70. Abeylath SC, Amiji MM. 'Click' synthesis of dextran macrostructures for combinatorialdesigned self-assembled nanoparticles encapsulating diverse anticancer therapeutics. Bioorg. Med. Chem. 19(21), 6167-6173 (2011).
71. Trommer H, Neubert RH. Overcoming the stratum corneum: the modulation of skin penetration. A review. Skin Pharmacol. Physiol. 19(2), 106-121 (2006).
72. Williams AC, Barry BW. Penetration enhancers. Adv. Drug Deliv. Rev. 56(5), 603-618 (2004).
73. Karande P, Jain A, Mitragotri S. Relationships between skin's electrical impedance and permeability in the presence of chemical enhancers. J. Control. Release 110(2), 307-313 (2006).
74. Rachakonda VK, Yerramsetty KM, Madihally SV, Robinson RL Jr, Gasem KA. Screening of chemical penetration enhancers for transdermal drug delivery using electrical resistance of skin. Pharm. Res. 25(11), 2697-2704 (2008).
75. Gu S, Gao J, Hou X et al. Effects of penetration enhancers on Shuangwu traumatic formula: in vitro percutaneous absorption and in vivo pharmacodynamic evaluation of an herb medicine. Eur. J. Pharm. Biopharm. 73(3), 385-390 (2009).
76. Fernando GJ, Chen X, Prow TW et al. Potent immunity to low doses of influenza vaccine by probabilistic guided microtargeted skin delivery in a mouse model. PLoS ONE 5(4), e10266 (2010).
77. Chen X, Prow TW, Crichton ML et al. Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin. J. Control. Release 139(3), 212-220 (2009).
78. Corbett HJ, Fernando GJ, Chen X, Frazer IH, Kendall MA. Skin vaccination against cervical cancer associated human papillomavirus with a novel microprojection array in a mouse model. PLoS ONE 5(10), e13460 (2010).
79. Prow TW, Chen X, Prow NA et al. Nanopatch-targeted skin vaccination against West Nile virus and Chikungunya virus in mice. Small 6(16), 1776-1784 (2010).
80. Quan FS, Kim YC, Yoo DG, Compans RW, Prausnitz MR, Kang SM. Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS ONE 4(9), e7152 (2009).
81. Gill HS, Söderholm J, Prausnitz MR, Sällberg M. Cutaneous vaccination using microneedles coated with hepatitis C DNA vaccine. Gene Ther. 17(6), 811-814 (2010).
82. Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG et al. Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS ONE 4(3), e4773 (2009).
83. Morefield GL, Tammariello RF, Purcell BK et al. An alternative approach to combination vaccines: intradermal administration of isolated components for control of anthrax, botulism, plague and staphylococcal toxic shock. J. Immune Based Ther. Vaccines 6, 5 (2008).
84. Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 27(3), 454-459 (2009).
85. Garland MJ, Caffarel-Salvador E, Migalska K, Woolfson AD, Donnelly RF. Dissolving polymeric microneedle arrays for electrically assisted transdermal drug delivery. J. Control. Release 159(1), 52-59 (2012).
86. Lee JW, Park JH, Prausnitz MR. Dissolving microneedles for transdermal drug delivery. Biomaterials 29(13), 2113-2124 (2008).
87. Sullivan SP, Koutsonanos DG, Del Pilar Martin M et al. Dissolving polymer microneedle patches for influenza vaccination. Nat. Med. 16(8), 915-920 (2010).
88. Raju PA, McSloy N, Truong NK, Kendall MA. Assessment of epidermal cell viability by near infrared multi-photon microscopy following ballistic delivery of gold micro-particles. Vaccine 24(21), 4644-4647 (2006).
89. Levin G, Gershonowitz A, Sacks H et al. Transdermal delivery of human growth hormone through RF-microchannels. Pharm. Res. 22(4), 550-555 (2005).
90. Ogura M, Sato S, Nakanishi K et al. In vivo targeted gene transfer in skin by the use of laser-induced stress waves. Lasers Surg. Med. 34(3), 242-248 (2004).
91. Lee S, McAuliffe DJ, Mulholland SE, Doukas AG. Photomechanical transdermal delivery of insulin in vivo. Lasers Surg. Med. 28(3), 282-285 (2001).
92. Boucaud A, Garrigue MA, Machet L, Vaillant L, Patat F. Effect of sonication parameters on transdermal delivery of insulin to hairless rats. J. Control. Release 81(1-2), 113-119 (2002).
93. Tokumoto S, Higo N, Sugibayashi K. Effect of electroporation and pH on the iontophoretic transdermal delivery of human insulin. Int. J. Pharm. 326(1-2), 13-19 (2006).
94. Tezel A, Paliwal S, Shen Z, Mitragotri S. Low-frequency ultrasound as a transcutaneous immunization adjuvant. Vaccine 23(29), 3800-3807 (2005).
95. Zhao YL, Murthy SN, Manjili MH, Guan LJ, Sen A, Hui SW. Induction of cytotoxic T-lymphocytes by electroporation-enhanced needle-free skin immunization. Vaccine 24(9), 1282-1290 (2006).
96. Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. Adv. Drug Deliv. Rev. 56(5), 619-658 (2004).
97. Cázares-Delgadillo J, Naik A, Ganem-Rondero A, Quintanar-Guerrero D, Kalia YN. Transdermal delivery of cytochrome C-a 12.4 kDa protein-across intact skin by constant-current iontophoresis. Pharm. Res. 24(7), 1360-1368 (2007).
98. Kalaria DR, Dubey S, Kalia YN. Clinical applications of transdermal iontophoresis. In: Topical and Transdermal Drug Delivery and Development. Watkinson AC, Benson HA (Eds). John Wiley & Sons Inc., NJ, USA, 67-83 (2012).
99. Murthy SN. Magnetophoresis: an approach to enhance transdermal drug diffusion. Pharmazie 54(5), 377-379 (1999).
100. Murthy SN, Hiremath SR. Physical and chemical permeation enhancers in transdermal delivery of terbutaline sulphate. AAPS PharmSciTech 2(1), E-TN1 (2001).
101. Namjoshi S, Caccetta R, Edwards J, Benson HA. Liquid chromatography assay for 5-aminolevulinic acid: application to in vitro assessment of skin penetration via dermaportation. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 852(1-2), 49-55 (2007).
102. Namjoshi S, Chen Y, Edwards J, Benson HA. Enhanced transdermal delivery of a dipeptide by dermaportation. Biopolymers 90(5), 655-662 (2008).
103. Krishnan G, Roberts MS, Grice J, Anissimov YG, Benson HA. Enhanced transdermal delivery of 5-aminolevulinic acid and a dipeptide by iontophoresis. Biopolymers 96(2), 166-171 (2011).
104. Sammeta SM, Repka MA, Narasimha Murthy S. Magnetophoresis in combination with chemical enhancers for transdermal drug delivery. Drug Dev. Ind. Pharm. 37(9), 1076-1082 (2011).
105. Lademann J, Richter H, Teichmann A et al. Nanoparticles-an efficient carrier for drug delivery into the hair follicles. Eur. J. Pharm. Biopharm. 66(2), 159-164 (2007).
106. Tinkle SS, Antonini JM, Rich BA et al. Skin as a route of exposure and sensitization in chronic beryllium disease. Environ. Health Perspect. 111(9), 1202-1208 (2003).
107. Rouse JG, Yang J, Ryman-Rasmussen JP, Barron AR, Monteiro-Riviere NA. Effects of mechanical flexion on the penetration of fullerene amino acid-derivatized peptide nanoparticles through skin. Nano Lett. 7(1), 155-160 (2007).
108. Moresi JM, Horn TD. Distribution of Langerhans cells in human hair follicle. J. Cutan. Pathol. 24(10), 636-640 (1997).
109. Liu X, Grice JE, Lademann J et al. Hair follicles contribute significantly to penetration through human skin only at times soon after application as a solvent deposited solid in man. Br. J. Clin. Pharmacol. 72(5), 768-774 (2011).
110. Toll R, Jacobi U, Richter H, Lademann J, Schaefer H, Blume-Peytavi U. Penetration profile of microspheres in follicular targeting of terminal hair follicles. J. Invest. Dermatol. 123(1), 168-176 (2004).
111. Lademann J, Patzelt A, Richter H, Antoniou C, Sterry W, Knorr F. Determination of the cuticula thickness of human and porcine hairs and their potential influence on the penetration of nanoparticles into the hair follicles. J. Biomed. Opt. 14(2), 021014 (2009).
112. Hojyo-Tomoka MT, Kligman AM. Does cellophane tape stripping remove the horny layer? Arch. Dermatol. 106(5), 767-768 (1972).
113. Kammerau B, Zesch A, Schaefer H. Absolute concentrations of dithranol and triacetyl-dithranol in the skin layers after local treatment: in vivo investigations with four different types of pharmaceutical vehicles. J. Invest. Dermatol. 64(3), 145-149 (1975).
114. Weigand DA, Gaylor JR. Removal of stratum corneum in vivo: an improvement on the cellophane tape stripping technique. J. Invest. Dermatol. 60(2), 84-87 (1973).
115. Kalia YN, Pirot F, Guy RH. Homogeneous transport in a heterogeneous membrane: water diffusion across human stratum corneum in vivo. Biophys. J. 71(5), 2692-2700 (1996).
116. Tsai JC, Shen LC, Sheu HM, Lu CC. Tape stripping and sodium dodecyl sulfate treatment increase the molecular weight cutoff of polyethylene glycol penetration across murine skin. Arch. Dermatol. Res. 295(4), 169-174 (2003).
117. El Maghraby GM, Williams AC, Barry BW. Can drug-bearing liposomes penetrate intact skin? J. Pharm. Pharmacol. 58(4), 415-429 (2006).
118. Choi MJ, Maibach HI. Liposomes and niosomes as topical drug delivery systems. Skin Pharmacol. Physiol. 18(5), 209-219 (2005).
119. Godin B, Touitou E. Ethosomes: new prospects in transdermal delivery. Crit. Rev. Ther. Drug Carrier Syst. 20(1), 63-102 (2003).
120. Benson HA. Transfersomes for transdermal drug delivery. Expert Opin. Drug Deliv. 3(6), 727-737 (2006).
121. Geusens B, Van Gele M, Braat S et al. Flexible nanosomes (SECosomes) enable efficient siRNA delivery in cultured primary skin cells and in the viable epidermis of ex vivo human skin. Adv. Funct. Mater. 20(23), 4077-4090 (2010).
122. Lehmann PA, Raney SG, Franz TJ. Skin permeation assessment in man: in vitro-in vivo correlation. In: Topical and Transdermal Drug Delivery and Development. Watkinson AC, Benson HA (Eds). John Wiley & Sons Inc., NJ, USA, 167-182 (2012).
123. Bronaugh RL, Stewart RF. Methods for in vitro percutaneous absorption studies IV: the flow-through diffusion cell. J. Pharm. Sci. 74(1), 64-67 (1985).
124. Feldmann RJ, Maibach HI. Absorption of some organic compounds through the skin in man. J. Invest. Dermatol. 54(5), 399-404 (1970).
125. Schäfer-Korting M, Bock U, Gamer A et al. Reconstructed human epidermis for skin absorption testing: results of the German prevalidation study. Altern. Lab. Anim. 34(3), 283-294 (2006).
126. Henning A, Neumann D, Kostka KH, Lehr CM, Schaefer UF. Influence of human skin specimens consisting of different skin layers on the result of in vitro permeation experiments. Skin Pharmacol. Physiol. 21(2), 81-88 (2008).
127. Alvarez-Román R, Naik A, Kalia YN, Fessi H, Guy RH. Visualization of skin penetration using confocal laser scanning microscopy. Eur. J. Pharm. Biopharm. 58(2), 301-316 (2004).
128. Tsai TH, Jee SH, Dong CY, Lin SJ. Multiphoton microscopy in dermatological imaging. J. Dermatol. Sci. 56(1), 1-8 (2009).
129. Sanchez WY, Prow TW, Sanchez WH, Grice JE, Roberts MS. Analysis of the metabolic deterioration of ex vivo skin from ischemic necrosis through the imaging of intracellular NAD(P)H by multiphoton tomography and fluorescence lifetime imaging microscopy. J. Biomed. Opt. 15(4), 046008 (2010).
130. Galletly NP, McGinty J, Dunsby C et al. Fluorescence lifetime imaging distinguishes basal cell carcinoma from surrounding uninvolved skin. Br. J. Dermatol. 159(1), 152-161 (2008).
131. König K, Uchugonova A, Gorjup E. Multiphoton fluorescence lifetime imaging of 3D-stem cell spheroids during differentiation. Microsc. Res. Tech. 74(1), 9-17 (2011).
132. Lin LL, Grice JE, Butler MK et al. Time-correlated single photon counting for simultaneous monitoring of zinc oxide nanoparticles and NAD(P)H in intact and barrier-disrupted volunteer skin. Pharm. Res. 28(11), 2920-2930 (2011).
133. Mélot M, Pudney PD, Williamson AM, Caspers PJ, Van Der Pol A, Puppels GJ. Studying the effectiveness of penetration enhancers to deliver retinol through the stratum corneum by in vivo confocal Raman spectroscopy. J. Control. Release 138(1), 32-39 (2009).
134. Peira E, Scolari P, Gasco MR. Transdermal permeation of apomorphine through hairless mouse skin from microemulsions. Int. J. Pharm. 226(1-2), 47-51 (2001).
135. Peltola S, Saarinen-Savolainen P, Kiesvaara J, Suhonen TM, Urtti A. Microemulsions for topical delivery of estradiol. Int. J. Pharm. 254(2), 99-107 (2003).
136. Rhee YS, Choi JG, Park ES, Chi SC. Transdermal delivery of ketoprofen using microemulsions. Int. J. Pharm. 228(1-2), 161-170 (2001).
137. Sintov AC, Shapiro L. New microemulsion vehicle facilitates percutaneous penetration in vitro and cutaneous drug bioavailability in vivo. J. Control. Release 95(2), 173-183 (2004).
138. Wu H, Ramachandran C, Bielinska AU et al. Topical transfection using plasmid DNA in a water-in-oil nanoemulsion. Int. J. Pharm. 221(1-2), 23-34 (2001).
139. Betz G, Aeppli A, Menshutina N, Leuenberger H. In vivo comparison of various liposome formulations for cosmetic application. Int. J. Pharm. 296(1-2), 44-54 (2005).
140. Christensen D, Korsholm KS, Rosenkrands I, Lindenstrøm T, Andersen P, Agger EM. Cationic liposomes as vaccine adjuvants. Expert Rev. Vaccines 6(5), 785-796 (2007).
141. Drulis-Kawa Z, Dorotkiewicz-Jach A. Liposomes as delivery systems for antibiotics. Int. J. Pharm. 387(1-2), 187-198 (2010).
142. Manconi M, Valenti D, Sinico C, Lai F, Loy G, Fadda AM. Niosomes as carriers for tretinoin. II. Influence of vesicular incorporation on tretinoin photostability. Int. J. Pharm. 260(2), 261-272 (2003).
143. Manosroi A, Khanrin P, Werner RG, Götz F, Manosroi W, Manosroi J. Entrapment enhancement of peptide drugs in niosomes. J. Microencapsul. 27(3), 272-280 (2010).
144. Ruckmani K, Sankar V. Formulation and optimization of zidovudine niosomes. AAPS PharmSciTech 11(3), 1119-1127 (2010).
145. Dubey V, Mishra D, Nahar M, Jain V, Jain NK. Enhanced transdermal delivery of an anti-HIV agent via ethanolic liposomes. Nanomedicine 6(4), 590-596 (2010).
146. Fang YP, Huang YB, Wu PC, Tsai YH. Topical delivery of 5-aminolevulinic acid-encapsulated ethosomes in a hyperproliferative skin animal model using the CLSM technique to evaluate the penetration behavior. Eur. J. Pharm. Biopharm. 73(3), 391-398 (2009).
147. Rao Y, Zheng F, Zhang X, Gao J, Liang W. In vitro percutaneous permeation and skin accumulation of finasteride using vesicular ethosomal carriers. AAPS PharmSciTech 9(3), 860-865 (2008).
148. Bendas ER, Tadros MI. Enhanced transdermal delivery of salbutamol sulfate via ethosomes. AAPS PharmSciTech 8(4), E107 (2007).
149. Alvi IA, Madan J, Kaushik D, Sardana S, Pandey RS, Ali A. Comparative study of transfersomes, liposomes, and niosomes for topical delivery of 5-fluorouracil to skin cancer cells: preparation, characterization, in-vitro release, and cytotoxicity analysis. Anticancer. Drugs 22(8), 774-782 (2011).
150. Hofer C, Hartung R, Göbel R, Deering P, Lehmer A, Breul J. New ultradeformable drug carriers for potential transdermal application of interleukin-2 and interferon-α: theoretic and practical aspects. World J. Surg. 24(10), 1187-1189 (2000).
151. Mahor S, Rawat A, Dubey PK et al. Cationic transfersomes based topical genetic vaccine against hepatitis B. Int. J. Pharm. 340(1-2), 13-19 (2007).
152. Farboud ES, Nasrollahi SA, Tabbakhi Z. Novel formulation and evaluation of a Q10-loaded solid lipid nanoparticle cream: in vitro and in vivo studies. Int. J. Nanomedicine 6, 611-617 (2011).
153. Gulbake A, Jain A, Khare P, Jain SK. Solid lipid nanoparticles bearing oxybenzone: in-vitro and in-vivo evaluation. J. Microencapsul. 27(3), 226-233 (2010).
154. Padois K, Cantiéni C, Bertholle V, Bardel C, Pirot F, Falson F. Solid lipid nanoparticles suspension versus commercial solutions for dermal delivery of minoxidil. Int. J. Pharm. 416(1), 300-304 (2011).
155. Schlupp P, Blaschke T, Kramer KD, Höltje HD, Mehnert W, Schäfer-Korting M. Drug release and skin penetration from solid lipid nanoparticles and a base cream: a systematic approach from a comparison of three glucocorticoids. Skin Pharmacol. Physiol. 24(4), 199-209 (2011).
156. Agrawal Y, Petkar KC, Sawant KK. Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis. Int. J. Pharm. 401(1-2), 93-102 (2010).
157. Chen J, Chen HY, Cui SS et al. Glucosamine derivative modified nanostructured lipid carriers for targeted tumor delivery. J. Mater. Chem. 22(12), 5770-5783 (2012).
158. Pardeike J, Schmidt C, Volz I, Müller RH. Nanostructured lipid carriers as delivery system for the phopholipase A2 inhibitors PX-18 and PX-13 for dermal application. Pharmazie 66(5), 357-361 (2011).
159. Puglia C, Sarpietro MG, Bonina F, Castelli F, Zammataro M, Chiechio S. Development, characterization, and in vitro and in vivo evaluation of benzocaine-and lidocaineloaded nanostructrured lipid carriers. J. Pharm. Sci. 100(5), 1892-1899 (2011).
160. Hafner A, Lovric J, Pepic I, Filipovic-Grcic J. Lecithin/chitosan nanoparticles for transdermal delivery of melatonin. J. Microencapsul. 28(8), 807-815 (2011).
161. Lboutounne H, Chaulet JF, Ploton C, Falson F, Pirot F. Sustained ex vivo skin antiseptic activity of chlorhexidine in poly(epsilon-caprolactone) nanocapsule encapsulated form and as a digluconate. J. Control. Release 82(2-3), 319-334 (2002).
162. Morgen M, Lu GW, Du D et al. Targeted delivery of a poorly water-soluble compound to hair follicles using polymeric nanoparticle suspensions. Int. J. Pharm. 416(1), 314-322 (2011).
163. Tomoda K, Terashima H, Suzuki K, Inagi T, Terada H, Makino K. Enhanced transdermal delivery of indomethacin using combination of PLGA nanoparticles and iontophoresis in vivo. Colloids Surf. B. Biointerfaces 92, 50-54 (2012).
164. Prausnitz MR. Microneedles for transdermal drug delivery. Adv. Drug Deliv. Rev. 56(5), 581-587 (2004).
165. Herwadkar A, Sachdeva V, Taylor LF, Silver H, Banga AK. Low-frequency sonophoresis mediated transdermal and intradermal delivery of ketoprofen. Int. J. Pharm. 423(2), 289-296 (2012).
166. Kanebako M, Inagi T, Takayama K. Transdermal delivery of indomethacin by iontophoresis. Biol. Pharm. Bull. 25(6), 779-782 (2002).